Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. -
SPECT and PET in ischemic heart failureAngelidis G, Giamouzis G, Karagiannis G et al.
-
Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative reviewBurlacu A, Simion P, Nistor I et al.
-
Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome TrialsOR Ghosh-Swaby, SG Goodman, LA Leite et al.
-
Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP TrialK Sharma, Stuart D. Russell and on behalf of the Osler Medical Housestaff.
-
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWT Abraham, JA Lindenfeld, P Ponikowski et al.
-
Vericiguat in Patients with Heart Failure and Reduced Ejection FractionPW Armstrong, B Pieske, the VICTORIA Study Group
-
Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) TrialB Pieske, MJ Patel, VICTORIA Study Group et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
